APS Inflammatory Bowel Diseases Translational Research Conference, Sept. 8-11

June 22, 2004

Bethesda, MD - (June 22, 2004) The American Physiological Society (APS) announces it is sponsoring a translational research conference entitled "Immunological and Pathophysiological Mechanisms in Inflammatory Bowel Diseases" from Sept. 8-11, 2004 in Snowmass, Colorado.

The keynote lecture, "IBD: Light at the End of the Tunnel?" will be delivered by Daniel Podolsky, M.D., professor of medicine at Harvard Medical School and chief of the gastrointestinal unit at the affiliated Massachusetts General Hospital.

The final panel of the meeting, featuring researchers from the Mayo Clinic, Cedars-Sinai Medical Center, University of Barcelona, Spain, and University of Bologna, Italy, will describe new therapeutic strategies in the treatment of IBD.

In addition to evening sessions involving research poster presentations, the meeting will feature symposia led by noted researchers on the following subjects:According to co-organizers Matthew Grisham, of Louisiana State University, Shreveport and Fabio Cominelli, of the University of Virginia, the IBD conference is the "first in a series of translational, that is, bench to bedside, conferences to be sponsored by APS aimed at bringing together internationally recognized scientists and clinicians as well as promising young investigators" in a variety of physiological subjects.

Speakers and other participants, many of whom will be presenting poster abstracts, come from all over world, and include researchers and students from the graduate through senior research/faculty level.

Abstracts already have been received from researchers working in Australia, Canada, Germany, Greece, Israel, Italy, Japan, the Netherlands, Puerto Rico, and Spain, as well as throughout the U.S.

Over the four days of sessions, participants will gain an in-depth understanding of the latest developments in research on the underlying mechanisms responsible for experimental and clinical IBD.

Reflecting the "translational" nature of the meetings sponsored by the American Physiological Society, clinical, pharmaceutical and biotech researchers will highlight novel IBD therapeutic strategies.

Media registration and information

Full information about the conference, including the detailed schedule, is at: http://www.the-aps.org/meetings/aps/snowmass/index.htm

Media wishing to attend part or all of the conference in person, and to arrange interviews in advance, should call or email APS communications contacts:

Mayer Resnick at 301.634.7209, mresnick@the-aps.org
Stacy Brooks at 301.634.7253, sbrooks@the-aps.org

APS website www.the-aps.org; next APS conference: "Exercise"

For more information about APS, its journals and publications, extensive educational and mentoring activities and other meetings, go to the APS website.

The "Press Room" section offers access to press releases and abstracts on research presented at past meetings as well as research reported in APS journals.

The next APS conference, "Integrative Biology of Exercise," is scheduled for October 6-9, 2004 in Austin, Texas. Information is available at:


The American Physiological Society (APS) was founded in 1887 to foster basic and applied science, much of it relating to human health. The Bethesda, MD-based Society has more than 10,000 members and publishes over 3,800 articles in its 14 peer-reviewed journals every year.

In May 2004, APS received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM).

American Physiological Society

Related Inflammatory Bowel Diseases Articles from Brightsurf:

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Management of inflammatory bowel diseases: Clinical perspectives
In a new special issue of Clinical Gastroenterology and Hepatology, the clinical practice journal of the American Gastroenterological Association (AGA), leading international experts provide a comprehensive update on the treatment of inflammatory bowel diseases (IBD) for the practicing clinician

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

FODMAPs diet relieves symptoms of inflammatory bowel disease
New research from King's College London has found that a diet low in fermented carbohydrates has improved certain gut symptoms and improved health-related quality of life for sufferers of inflammatory bowel disease (IBD).

Read More: Inflammatory Bowel Diseases News and Inflammatory Bowel Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.